IDENTIFYING AND TREATING AUTOIMMUNE NEUROLOGICAL DISORDERS
With
Associate Professor Sudarshini (Darshi) Ramanathan,
Neurologist & Head of Translational Neuroimmunology Group
Faculty of Medicine and Health
University of Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | April 2026
Associate Professor Sudarshini Ramanathan is a neurologist and clinician scientist whose work focuses on autoimmune neurological disorders. Her research has helped identify new neurological syndromes due to antibody-mediated demyelination and encephalitis, and improve diagnostic tools and treatment guidelines for patients with autoimmune diseases affecting the brain, spinal cord, muscles and nerves.
Associate Professor Ramanathan’s research program aims to improve our understanding of underlying disease pathogenesis with a focus towards ‘precision medicine’ in neuroimmunology – both with diagnosis and therapeutics. Her research focuses on defining the clinical, radiological, and immunophenotypic profiles of specific pathogenic autoantibodies; understanding what triggers autoimmunity and disruption of immune tolerance; and the cellular and humoural mechanisms of action of autoantibodies and how this might be translated into refining novel therapeutic approaches.
Her work thus far has resulted in the enhanced recognition of novel treatable neurological conditions, important biological insights into the pathophysiology of these disorders, and the development of diagnostic criteria and therapeutic approaches to improve outcomes in vulnerable patients who otherwise risk chronic disability.
Associate Professor Ramanathan heads the Translational Neuroimmunology Group at the Faculty of Medicine and Health, University of Sydney; and also runs a neuroimmunology clinic at Concord Hospital. She supervises and mentors a research team of PhD and Masters candidates, postdoctoral fellows, and clinician researchers. Her research has been recognised by the Leonard Cox Award for Excellence in Neuroscience research and the NSW Premier’s Prize Award for Early Career Researchers (Biological Sciences) in 2022.
Source: Supplied
https://orcid.org/0000-0002-0294-9768
-
Pregnancy in women with chronic kidney disease
Professor Shilpanjali Jesudason is an academic nephrologist and Head of Department at the Royal Adelaide Hospital’s Central Northern Adelaide Renal and Transplant Service, South Australia.
From 2017-2020, she was the Clinical Director of Kidney Health Australia, the peak body for patients with kidney disease. In this role she developed a passion for advancing kidney disease education in primary care.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
